The invention provides novel pharmaceutical compositions comprising as the active
ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid
receptors. In particular, the compounds of the invention binds efficiently to CB2
but do not bind to CB1. The compounds show no activity in behavioral tests in mice
which together have been shown to be specific for tetrahydrocannabinol (THC)-type
activity in the central nervous system mediated by CB1 but reduce blood pressure,
block intestinal motility, and elicit anti-inflammatory and peripheral analgetic
activity. The invention also relates to methods of treating, preventing, or managing
hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases,
and tumors with the compounds of the invention.
